MedTrace Logo

Argus® II Retinal Stimulation System Feasibility Protocol

NCT00407602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-20

Study results available
· View outcomes & findings →

Summary

Investigational Phase of the Study:

The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa.

Post-Approval Phase of the Study:

To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System

Conditions

Interventions

DEVICE

Implant of Argus II Retinal Prosthesis

epiretinal implantation of device

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Second Sight Medical Products

    lead INDUSTRY

Principal Investigators

  • Anne-Marie Ripley · Second Sight Medical Products

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States
  • France
  • Mexico
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407602 on ClinicalTrials.gov